HB9102, the Biotech Investment National Security Act of 2026 (BINSA Act), would expand the federal outbound investment screening framework under title VIII of the Defense Production Act to treat biotechnology as a covered sector. The bill defines biotechnology broadly to include the research, development, manufacturing, and commercialization of pharmaceutical products, biological products, and therapeutic compounds, including drug discovery platforms, clinical research and development, biologics manufacturing, and related intellectual property and know-how. It also adds licensing of a prohibited technology from a covered foreign person as a covered transaction.
The bill directs the Secretary of the Treasury to issue regulations within one year to further define the biotechnology sector for purposes of prohibited and notifiable technology categories. In doing so, Treasury must consult with Defense, Health and Human Services, and the Director of National Intelligence, and must give special attention to licensing, joint ventures, and equity investments involving Chinese biotechnology firms. The bill also requires the Secretary of Defense to report within 60 days on whether U.S. capital flows into China’s biotechnology sector harm national security or military readiness.
The bill’s stated purpose is to prevent U.S. capital, intellectual property, and know-how from accelerating China’s biotechnology and pharmaceutical capabilities. It would therefore affect U.S. investors, pharmaceutical companies, biotech firms, and parties involved in cross-border licensing, joint ventures, and equity investments, especially where the counterparty is a covered foreign person tied to China. It also explicitly excludes agricultural biotechnology, unrelated industrial fermentation, and basic academic research without direct pharmaceutical or therapeutic application from the intended scope.
The available context shows little recorded debate or voting activity: the bill was introduced in the House and referred to the Committee on Financial Services, with no committee transcript or vote history provided. Based on the bill text, the overall sentiment appears strongly national-security oriented and supportive of tighter restrictions on biotech-related outbound investment to China. The main point of contention likely concerns how broadly biotechnology should be defined and whether the rules could unintentionally capture legitimate commercial, research, or licensing activity, which the bill attempts to limit by excluding certain non-pharmaceutical areas.
HB9102 would amend section 809 of the Defense Production Act of 1950 to add biotechnology to the list of sectors subject to outbound investment screening, including both prohibited and notifiable technology categories. It would also require Treasury rulemaking to define the sector and would mandate a Defense Department report on the national security effects of U.S. capital flows into China’s biotech sector. The bill would primarily affect investors, pharmaceutical and biotech companies, licensors, joint venture partners, and entities dealing with Chinese biotechnology firms, while expressly carving out agricultural biotechnology and unrelated research.
No votes or committee debate are provided, so there is no recorded legislative opposition or support in the supplied materials beyond the bill’s introduction. The text itself reflects a clear pro-national-security posture, with bipartisan sponsorship indicated by the named House sponsors. Overall sentiment appears favorable toward restricting sensitive biotech transfers to China, with the bill framed as a response to strategic competition and dependency risks.
The likely areas of contention are the breadth of the biotechnology definition and the reach of outbound investment screening into ordinary commercial activity. The bill tries to narrow that concern by excluding agricultural biotechnology, industrial fermentation unrelated to pharmaceutical or therapeutic production, and basic academic research without direct application. Another possible point of dispute is whether licensing transactions, joint ventures, and equity investments should all be treated as priority categories for restriction, especially where they involve intellectual property or know-how rather than direct ownership of companies.